Endocrinologist
Victor Chang Cardiac Research Institute
Sydney, Australia
Professor Jerry Greenfield is an endocrinologist and clinical researcher. He is Head of the Department of Endocrinology and Director, Diabetes Services, at St Vincent’s Hospital. His current positions and roles include Professor of Medicine at the University of New South Wales and Editorial Board member at Clinical Obesity.
Professor Greenfield previously held an NHMRC Neil Hamilton Fairley Postdoctoral Research Fellowship, which allowed him to study in the Departments of Medicine and Clinical Biochemistry, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK (2005-6, Supervisors: Professor Stephen O’Rahilly and Dr Sadaf Farooqi). He undertook a PhD at the Garvan Institute of Medical Research from 2001–2004. He graduated from the Faculty of Medicine with Honours (class 1) from the University of NSW in 1995.
Over the past five years, Professor Greenfield has published more than 200 manuscripts in top-ranked endocrinology and diabetes journals. He has recently been invited to speak at international conferences. Professor Greenfield and Dr Jennifer Snaith recently established the Australian Collaborative Towards Adjunctive Therapies in Type One Diabetes group (ACT-T1D), which aims to facilitate the generation of clinical trial evidence for adjunctive therapies in type 1 diabetes. Their novel strategy aims to improve the access of repurposed medications to the people with type 1 diabetes at greatest cardiovascular risk. This strategy signals a departure from current insulin-only standard of care, facilitating improved access to adjunctive medications such as metformin and semaglutide. Their team, the suite of gold-standard investigative clinical research tools, the established collaborations with Australian researchers and partnerships with Novo Nordisk, the Australian Diabetes Society and the Juvenile Diabetes Research Foundation, are a perfect union to ensure successful execution of adjunctive trials, resulting in the greatest impact for people living with type 1 diabetes to reduce their cardiovascular burden.
Disclosure information not submitted.
MTP31 - Use of Adjunctive Therapies to Target Cardiometabolic Risk in Type 1 Diabetes
Monday, June 15, 2026
2:35 PM - 3:15 PM CT